Sunshine Biopharma Inc (SBFM)

[VortMax]

How about $7B+ yearly in Sales?

Herceptin® by Roche $6.86B in 2014 sales for breast cancer.

http://www.statista.com/statistics/288538/top-cancer-drugs-based-on-revenue/

Adva-27a® by Sunshine $6.86B+ ?

https://ca.finance.yahoo.com/news/breast-cancer-news-geron-drug-fails-herceptin-may-140500811.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86467960

Roche’s Herceptin® may be facing some obstacles in the near term and the patent cliff in 2014, but sales have been steadily increasing since its 2006 FDA approval. Notably, the drug only targets about 15 to 20 percent of breast cancer patients. Gauging potential market value for Sunshine’s Adva-27a from Roche’s sales of Herceptin, it is discernible that its market capture could be far greater being that the TOP2-positive breast cancer patient population is much larger.

Avastin® Ousted by FDA for breast cancer, step in Sunshine Biopharma

http://www.biotechstocktrader.com/avastin-ousted-by-fda-for-breast-cancer-sunshine-biopharma-gears-up-for-clinicals-321/

According to the Breast Cancer Organization of the USA, it is estimated that more than 260,000 new cases of breast cancer were diagnosed last year. The dreaded disease has rightfully never slipped from the spotlight, but has garnered stronger attention again with the latest news about Avastin®. By targeting drug-resistant cancer strains and outpacing Etoposide, Sunshine Biopharma’s Adva-27 is right in the mix with other anti-cancer drugs in development. Just as Herceptin® revolutionized HER2 therapies for breast cancer – and generated nearly $7 billion in 2010 sales alone – Sunshine is looking to do the same with its Top2 drug in the future.